All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Identification of selective, ligand-efficient ATP-competitive inhibitors of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) for the potential treatment of cancer was discussed by Bristol Myers Squibb Co. (BMS).